BNP Paribas Financial Markets
KALV

BNP Paribas Financial Markets’s KalVista Pharmaceuticals KALV Stock Holding History

BNP Paribas Financial Markets’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$241K Buy
11,974
+7,884
+193% +$127K ﹤0.01% 3967
2025
Q4 		$66.1K Sell
4,090
-3,704
-48% -$49.1K ﹤0.01% 4564
2025
Q3 		$94.9K Buy
7,794
+3,753
+93% +$51.9K ﹤0.01% 4326
2025
Q2 		$45.7K Buy
4,041
+1,292
+47% +$15.8K ﹤0.01% 4291
2025
Q1 		$31.7K Sell
2,749
-3,503
-56% -$35.8K ﹤0.01% 4423
2024
Q4 		$53K Sell
6,252
-37,044
-86% -$384K ﹤0.01% 4407
2024
Q3 		$501K Buy
43,296
+40,280
+1,336% +$507K ﹤0.01% 2858
2024
Q2 		$35.5K Sell
3,016
-14,997
-83% -$175K ﹤0.01% 3533
2024
Q1 		$214K Buy
18,013
+8,750
+94% +$117K ﹤0.01% 3232
2023
Q4 		$113K Buy
9,263
+5,573
+151% +$50.7K ﹤0.01% 3359
2023
Q3 		$35.5K Sell
3,690
-9,112
-71% -$93.1K ﹤0.01% 3510
2023
Q2 		$115K Buy
12,802
+885
+7% +$8.16K ﹤0.01% 3217
2023
Q1 		$93.7K Buy
11,917
+5,808
+95% +$43.3K ﹤0.01% 3337
2022
Q4 		$41.3K Sell
6,109
-1,134
-16% -$6.07K ﹤0.01% 3456
2022
Q3 		$105K Buy
7,243
+1,285
+22% +$18K ﹤0.01% 3748
2022
Q2 		$58.6K Buy
5,958
+4,189
+237% +$46.2K ﹤0.01% 3520
2022
Q1 		$26.1K Sell
1,769
-3,003
-63% -$43.1K ﹤0.01% 3686
2021
Q4 		$63.1K Buy
4,772
+1,173
+33% +$18.7K ﹤0.01% 3696
2021
Q3 		$62.8K Buy
3,599
+2,831
+369% +$57.4K ﹤0.01% 3447
2021
Q2 		$18.4K Sell
768
-7,606
-91% -$199K ﹤0.01% 3552
2021
Q1 		$215K Buy
8,374
+5,417
+183% +$142K ﹤0.01% 3009
2020
Q4 		$56.2K Sell
2,957
-581
-16% -$9.96K ﹤0.01% 3502
2020
Q3 		$44.5K Buy
3,538
+2,390
+208% +$29.9K ﹤0.01% 3522
2020
Q2 		$13.9K Sell
1,148
-3,456
-75% -$36.8K ﹤0.01% 3563
2020
Q1 		$35.2K Buy
4,604
+2,803
+156% +$37.8K ﹤0.01% 3713
2019
Q4 		$32.1K Buy
1,801
+327
+22% +$4.27K ﹤0.01% 3858
2019
Q3 		$17.1K Buy
1,474
+1,406
+2,068% +$22.7K ﹤0.01% 4013
2019
Q2 		$1.51K Buy
+68
New +$1.59K ﹤0.01% 4345
2016
Q1 		– Sell
-200
Closed -$10.2K – 2880
2015
Q4 		$10.2K Buy
200
+3
+2% +$157 ﹤0.01% 3403
2015
Q3 		$9.86K Buy
+197
New +$16.8K ﹤0.01% 3427

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BNP Paribas Financial Markets's KALV Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its KalVista Pharmaceuticals (KALV) stake by 193% in Q1 2026, buying an estimated $127K and bringing the position to 11,974 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #3967.

BNP Paribas Financial Markets first reported a position in KALV in Q3 2015 and has held it in 30 quarters since. The position peaked at $501K in Q3 2024. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • BNP Paribas Financial Markets held 11,974 shares of KalVista Pharmaceuticals worth $241K as of Q1 2026.
  • BNP Paribas Financial Markets bought 7,884 KalVista Pharmaceuticals shares in Q1 2026, an estimated $127K.
  • KalVista Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3967 holding.
  • BNP Paribas Financial Markets first reported a position in KalVista Pharmaceuticals in Q3 2015 and has held it in 30 quarters since.
  • BNP Paribas Financial Markets's KalVista Pharmaceuticals position peaked at $501K in Q3 2024.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.